Study Title
Evaluating in Vivo PARP-1 Expression With 18F-FluorThanatrace Positron Emission Tomography (PET/CT) in Patients With Metastatic Prostate Cancer
Study Details
Description:
Up to 30 men with metastatic prostate cancer will undergo up to 2 FTT PET/CT scans to look at PARP activity in sites of known cancer. Subjects will undergo a baseline scan prior to starting new therapy and a second, optional, post-therapy scan 1-21 days after the start of treatment. Tissue from a clinical or research biopsy will be compared to imaging measures, if available.
Sponsor:
Abramson Cancer Center of the University of Pennsylvania
Contacts:
Erin Schubert, BAerin.schubert@pennmedicine.upenn.edu
215-573-6569
Ashley Veronsky, BAashley.veronsky@pennmedicine.upenn.edu
215-898-4346
Government Study Link:
NCT05242744 - Click here to see study onClinicalTrials.gov
© 2021 XCancer Software LLC
Contact XCancer: 402-991-8468